Drug intelligence / Profile preview

metronidazole + furazolidone

Development stage: Unknown
Lead developer: Jinzhou Jiutai Pharmaceutical
Modality: Small Molecules
Administration: Vaginal

Overview

Metronidazole + furazolidone (brand name: Jiutai Kunbao) is an approved small molecule combination gynecological drug developed and manufactured by Jiutai Pharmaceutical. It is formulated as a vaginal suppository containing two active ingredients: metronidazole, a nitroimidazole that targets DNA synthesis in anaerobic bacteria and protozoa, and furazolidone, a nitrofuran antibiotic/antiprotozoal that inhibits bacterial enzyme systems. The drug is indicated for the treatment of cervicitis, cervical erosion, trichomonas vaginitis, bacterial vaginitis, and fungal vaginitis.

Brand names: Jiutai Kunbao九泰坤宝
Other names: Metronidazole Furazolidone suppositoriesMetronidazole and Furazolidone Suppositories甲硝唑呋喃唑酮栓

Targets

MAOA (Monoamine oxidase A)MAOB (Monoamine oxidase B)DNA

Beyond the preview

Go deeper on metronidazole + furazolidone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on metronidazole + furazolidone.